Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 2/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | MAG | P20916 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797801 | 1.00 | L3MBTL1 (0.40) | L3MBTL1SELPTLR4MAGBCHE | |
| SCHEMBL10417607 | 1.00 | L3MBTL1 (0.40) | L3MBTL1SELPTLR4MAGBCHE | |
| SCHEMBL6797796 | 1.00 | L3MBTL1 (0.40) | L3MBTL1SELPTLR4MAGBCHE | |
| SCHEMBL10824776 | 1.00 | L3MBTL1 (0.40) | L3MBTL1SELPTLR4MAGBCHE | |
| SCHEMBL6807462 | 1.00 | L3MBTL1 (0.40) | L3MBTL1SELPTLR4MAGBCHE | |
| SCHEMBL8434005 | 0.94 | L3MBTL1 (0.40) | L3MBTL1MAGTRPV1MCHR1 | |
| SCHEMBL10417606 | 0.89 | L3MBTL1 (0.41) | L3MBTL1SELPMAGBCHEACHE | |
| SCHEMBL8431552 | 0.89 | L3MBTL1 (0.42) | L3MBTL1SELPMCHR1 | |
| SCHEMBL10610859 | 0.88 | TLR4 (0.42) | L3MBTL1SELPTLR4 | |
| SCHEMBL10610554 | 0.88 | TLR4 (0.42) | L3MBTL1SELPTLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072767-A1 | Glucopyranose derivatives and medicaments for preventing and/or treating HIV infection diseases comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-04-15 | — | — | US | disclosed |
| EP-1095653-A9 | GLUCOPYRANOSE DERIVATIVES AND PREVENTIVES AND/OR REMEDIES FOR HIV INFECTION CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1095653-A1 | GLUCOPYRANOSE DERIVATIVES AND PREVENTIVES AND/OR REMEDIES FOR HIV INFECTION CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072767-A1 | Glucopyranose derivatives and medicaments for preventing and/or treating HIV infection diseases comprising the same as an active ingredient | UGGT1, SLC5A1, G6PD | L3MBTL1 779/4885SELP 1329/4885TLR4 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.